Latest Insider Transactions at Spring Works Therapeutics, Inc. (SWTX)
This section provides a real-time view of insider transactions for Spring Works Therapeutics, Inc. (SWTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of SpringWorks Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of SpringWorks Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 02
2023
|
Tai An Lin Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,000
+50.0%
|
-
|
|
Sep 01
2023
|
James Cassidy Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,292
-2.44%
|
$38,760
$30.33 P/Share
|
|
Jul 19
2023
|
Julie Hambleton Director |
SELL
Open market or private sale
|
Direct |
2,418
-34.22%
|
$70,122
$29.31 P/Share
|
|
Jun 30
2023
|
L. Mary Smith Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,720
+2.56%
|
-
|
|
Jun 30
2023
|
James Cassidy Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,720
+9.75%
|
-
|
|
Jun 20
2023
|
Julie Hambleton Director |
SELL
Open market or private sale
|
Direct |
2,400
-25.35%
|
$62,400
$26.92 P/Share
|
|
May 24
2023
|
Jeffrey Lawrence Schwartz Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,648
+30.54%
|
-
|
|
May 24
2023
|
Carlos Alban Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,648
+24.02%
|
-
|
|
May 24
2023
|
Alan Fuhrman Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,648
+30.54%
|
-
|
|
May 24
2023
|
Julie Hambleton Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,648
+32.93%
|
-
|
|
May 24
2023
|
Freda C Lewis Hall Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,648
+30.54%
|
-
|
|
May 24
2023
|
Daniel Lynch Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,648
+1.52%
|
-
|
|
Apr 03
2023
|
Bhavesh Ashar Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,375
-3.05%
|
$34,375
$25.25 P/Share
|
|
Mar 16
2023
|
Jeffrey Lawrence Schwartz Director |
SELL
Open market or private sale
|
Indirect |
1,750,000
-36.22%
|
$49,000,000
$28.5 P/Share
|
|
Mar 15
2023
|
Julie Hambleton Director |
SELL
Open market or private sale
|
Direct |
1,106
-18.67%
|
$34,286
$31.5 P/Share
|
|
Jan 26
2023
|
Daniel Pichl Chief People Officer |
SELL
Open market or private sale
|
Direct |
858
-2.38%
|
$26,598
$31.0 P/Share
|
|
Jan 07
2023
|
Herschel S Weinstein General Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
909
-2.47%
|
$23,634
$26.41 P/Share
|
|
Jan 07
2023
|
L. Mary Smith Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,068
-0.5%
|
$27,768
$26.41 P/Share
|
|
Jan 07
2023
|
Perier I Francis Jr Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,090
-2.45%
|
$28,340
$26.41 P/Share
|
|
Jan 07
2023
|
Daniel Pichl Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
546
-1.49%
|
$14,196
$26.41 P/Share
|
|
Jan 07
2023
|
Badreddin Edris Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,483
-0.62%
|
$38,558
$26.41 P/Share
|
|
Jan 07
2023
|
Saqib Islam Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,097
-0.45%
|
$106,522
$26.41 P/Share
|
|
Jan 07
2023
|
Michael Nofi Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
409
-2.37%
|
$10,634
$26.41 P/Share
|
|
Jan 06
2023
|
Daniel Pichl Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,719
-4.49%
|
$46,413
$27.52 P/Share
|
|
Jan 06
2023
|
Herschel S Weinstein General Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
1,782
-4.63%
|
$48,114
$27.52 P/Share
|
|
Jan 06
2023
|
Bhavesh Ashar Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,665
-3.56%
|
$44,955
$27.52 P/Share
|
|
Jan 06
2023
|
Michael Nofi Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
783
-4.34%
|
$21,141
$27.52 P/Share
|
|
Jan 06
2023
|
L. Mary Smith Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,452
-1.14%
|
$66,204
$27.52 P/Share
|
|
Jan 06
2023
|
James Cassidy Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,263
-2.6%
|
$34,101
$27.52 P/Share
|
|
Jan 06
2023
|
Badreddin Edris Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,326
-1.37%
|
$89,802
$27.52 P/Share
|
|
Jan 06
2023
|
Saqib Islam Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,400
-0.92%
|
$226,800
$27.52 P/Share
|
|
Jan 06
2023
|
Perier I Francis Jr Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,374
-5.06%
|
$64,098
$27.52 P/Share
|
|
Jan 05
2023
|
Daniel Pichl Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,425
+33.64%
|
-
|
|
Jan 05
2023
|
Herschel S Weinstein General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
19,425
+33.52%
|
-
|
|
Jan 05
2023
|
Bhavesh Ashar Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,663
+32.64%
|
-
|
|
Jan 05
2023
|
Michael Nofi Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,713
+34.99%
|
-
|
|
Jan 05
2023
|
L. Mary Smith Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,663
+9.51%
|
-
|
|
Jan 05
2023
|
James Cassidy Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,663
+31.85%
|
-
|
|
Jan 05
2023
|
Badreddin Edris Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,994
+12.32%
|
-
|
|
Jan 05
2023
|
Saqib Islam Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
84,175
+8.4%
|
-
|
|
Jan 05
2023
|
Perier I Francis Jr Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,425
+29.28%
|
-
|
|
Sep 12
2022
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
153,897
-1.34%
|
$4,770,807
$31.97 P/Share
|
|
Aug 09
2022
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
69,568
-1.19%
|
$2,574,016
$37.47 P/Share
|
|
Aug 08
2022
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
205,000
-3.4%
|
$7,790,000
$38.33 P/Share
|
|
Jul 18
2022
|
L. Mary Smith Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,551
-0.8%
|
$43,428
$28.47 P/Share
|
|
Jul 18
2022
|
Michael F. Burgess Head of Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
3,103
-5.89%
|
$86,884
$28.47 P/Share
|
|
Jul 14
2022
|
Carlos Alban Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,058
+50.0%
|
-
|
|
Jun 30
2022
|
L. Mary Smith Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,092
+3.04%
|
-
|
|
Jun 30
2022
|
Michael F. Burgess Head of Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
12,185
+18.78%
|
-
|
|
Jun 01
2022
|
Michael F. Burgess Head of Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
2,672
-6.19%
|
$50,768
$19.61 P/Share
|